1. Drögemöller B*, Wright G*, Shih J, Aminkeng F, Amstutz U, Hayden MR, Ross C, Carleton B; CPNDS Clinical Recommendation Group. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast Cancer Res Treat 2018; doi: 10.1007/s10549-018-5027-0.
    *These authors contributed equally to the work

  2. Kowalec K*, Wright GEB*, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis. Nat Genet. 2018;50:1081-5.

  3. Wright GEB, Amstutz U, Drögemöller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC, Ross CJD; Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2018; doi: 10.1002/cpt.1179

  4. Tanoshima R, Khan A, Biala AK, Trueman JN, Drögemöller BI, Wright GEB, Hasbullah JS, Groeneweg GSS, Ross CJD, Carleton BC. Analyses of Adverse Drug Reactions Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety (CPNDS) database. J Clin Pharmacol. 2018 Nov 19. doi: 10.1002/jcph.1336.

  5. Drögemöller BI, Brooks B, Critchley C, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Hayden MR, Gelmon KA, Carleton BC, Ross CJD. Further evidence for the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients. Clin Cancer Res. 2018; pii: clincanres.2810.2017.

  6. Drögemöller BI*, Monzon JG*, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol. 2017;3(11):1558-62. 
    *These authors contributed equally to this publication.


  1. Co-principal investigator for BC Children’s Research Institute Evidence to Innovation Seed Grant entitled Genome-wide association study of L-asparaginase-induced pancreatitis in pediatric cancer (2017)

  2. Co-investigator for CIHR Project Scheme Grant entitled Discovery, validation, and pre-clinical development of novel strategies to prevent anthracycline-induced cardiotoxicity(2017-2022)

  3. BC Children’s Hospital Research Outstanding Achievement by a Postdoctoral Fellow (2017)

  4. CIHR Postdoctoral Fellowship for project entitled Identification of the genetic variants involved in the development of severe adverse drug reactions in cancer patients treated with cisplatin (2017-2019)

  5. MSFHR Postdoctoral Fellowship for project entitled Unraveling the genetics of severe reactions to chemotherapy: Moving towards maximum benefit with minimal harm (2017-2018)
  6. CIHR Drug Safety and Effectiveness Cross‐Disciplinary Training (DSECT) Program for project entitled Genome-wide association study of L-asparaginase-induced pancreatitis in pediatric cancer patients (2017-2018)

  7. Child and Family Research Institute Hoffmeister fellowship for project entitled A comprehensive analysis of the genomic and clinical factors contributing to the occurrence of cisplatin-induced ototoxicity (2015-2016)

  8. Best Basic Science and Overall Poster Presentation at BC Children’s Hospital Research Evidence to Innovation Research Day for poster entitled Genetic variation in SLC16A5 confers protection from cisplatin-induced ototoxicity in adult testicular cancer patients (2016)

  9. Best Poster Presentation at the BC Children’s Hospital Research Trainee Forum for poster entitled Genome-wide association study of L-asparaginase-induced pancreatitis in children (2015)